Analysis: Morepen Laboratories Limited

NSE:MOREPENLAB Pharma - API & CRAMS Market cap: ₹6.4K cr

Growth thesis

Morepen Laboratories produces APIs (loratadine, atorvastatin) and medical devices (glucometers, BP monitors). The company guided 10-15% revenue growth for FY26 but nine-month revenue grew only 6.5%, with Q3 EBITDA margins falling to 9% from 12% in Q1. API capacity expanded to 514 KL (of 600 KL target) and medical devices grew 15% QoQ in May 2025, but management's 15-20% CAGR and 3-4% margin expansion targets remain unmet. New product launches (resmetirom, bempedoic acid) and device exports to Qatar/Oman are advancing, but API price erosion, U.S. tariff risks, and delayed formulation scaling (medical reps at 400 vs 1,200 target) persist as execution gaps.

Why is Morepen Laboratories Limited stock rising?

API manufacturing capacity expansion from 314 KL to 600 KL, with completion targeted within FY26
Medical devices capacity expansion: glucometer to 36 lakh meters per annum, test strips to 60 crore strips per annum, BP monitors nearly doubling to 18 lakh units
Formulation sales force to double from 200 to 400 medical representatives within the year, scaling to 1,200 over three years
Resmetirom (first-in-class NASH drug) filed for DCGI approval in India, with API manufactured in-house; seeking global and domestic partnerships
New API pipeline (diabetic, cardiac, anti-allergic molecules) expected to drive higher growth as patent expiries occur

Research report

companyname: Morepen Laboratories Limited ticker: MOREPENLAB sector: Pharmaceuticals & Medical Devices Morepen Laboratories Limited is a 40-year-old pharmaceutical and medical devices company that operates three distinct businesses under one roof: Active Pharmaceutical Ingredients (APIs), finished formulations (branded prescription and over-the-counter products), and home diagnostic medical devices (glucometers, blood pressure monitors, thermometers, nebulizers, ortho supports). The company man...

Read the full report →

Catalysts

capex, margin expansion, regulatory approval, geographic expansion

Growth guidance

10-15% revenue growth for FY26

Management consistency

mixed

RS rating: 99 Stage: Stage 2

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Morepen Laboratories Limited and 4,900+ companies.

5-day free pass. No card required.